Updated Jul 16, 2026
Ausiello Dennis A has filed 4 SEC Form 4 filings across 3 companies in the last 90 days — selling. Lifetime open-market sales: $13.73M.

Dennis A. Ausiello is a corporate director known for his involvement with several biotechnology companies, including Rani Therapeutics Holdings, Alnylam Pharmaceuticals, and Seres Therapeutics. He has held various roles in the pharmaceutical industry, contributing to advancements in RNA interference therapeutics.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-22 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | A — Grant or award | 671 | $0.00 | |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 641 | $442.66 | $284K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.2K | $441.88 | $532K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.2K | $440.54 | $545K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 5.3K | $439.27 | $2.33M |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 2.1K | $438.34 | $914K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.9K | $437.56 | $841K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 5.4K | $436.00 | $2.34M |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 7.7K | $435.40 | $3.34M |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 2.1K | $434.50 | $912K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.9K | $432.94 | $839K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 2.0K | $430.81 | $855K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | M — Option exercise | 3.5K | $189.87 | $656K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | M — Option exercise | 4.0K | $171.95 | $693K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | M — Option exercise | 5.2K | $151.22 | $791K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | M — Option exercise | 4.6K | $148.77 | $682K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | M — Option exercise | 5.2K | $128.31 | $661K |
| 2025-08-14 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | M — Option exercise | 9.0K | $72.01 | $648K |
| 2025-05-08 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | A — Grant or award | 775 | $0.00 |
Dennis A. Ausiello is a corporate director known for his involvement with several biotechnology companies, including Rani Therapeutics Holdings, Alnylam Pharmaceuticals, and Seres Therapeutics. He has held various roles in the pharmaceutical industry, contributing to advancements in RNA interference therapeutics.…
4 primary Form 4 filings in the last 90 days, covering 3 companies.
Recorded transactions: 0 open-market purchases () and 11 open-market sales ($13.73M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Ausiello Dennis A profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.